Salvage focal therapy and radical prostatectomy show similar cancer-specific survival but differ in complications, and a biomarker-driven, patient-centered approach (including reirradiation) is needed for personalized management.
Abstract
Highlights • Salvage focal therapy and radical prostatectomy show similar cancer-specific survival but differ in complications.• Lack of PSMA PET/CT and genomic risk assessment limits generalizability of current comparisons.• A biomarker-driven, patient-centered approach (including reirradiation) is needed for personalized management.
Take Home Message PSMA PET-derived volumetric data hold the potential to personalize treatment strategies depending on treatment response. Comprehensive data on PSMA expression dynamics, however, are still needed before this approach can be implemented in routine clinical practice.
J. Le Guévelou, M. Bauckneht, T. Soeterik et al.· European Urology Open Scienc...· 0 citations
This cohort study examines time to next treatment and overall survival associated with initiation of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) among US patients with metastatic androgen pathway modulator–resistant prostate cancer.
Varun Nandakumar, Y. Jo, M. Ostrowski et al.· JAMA Network Open· 0 citations
, recurrence, treatment response, and treatment-related risks. Several studies also illustrate a broader shift toward automation, multimodal data fusion, and clinically scalable arti fi cial intelligence (AI) pipelines, including applications to histological images and the integration of histopathology with RNA sequenci...
Arka Bhowmik, Sunitha B. Thakur, A. Bitencourt et al.· Frontiers in Oncology· 0 citations
Metastasis-free survival (MFS) may not have the same meaning after radical prostatectomy (RP) and radiotherapy (RT), largely because RT is typically combined with prolonged androgen-deprivation therapy (ADT), which can delay the clinical emergence of metastases. Therefore, MFS benefits cannot be assumed to have the sam...
M. Baboudjian, Alessandro Uleri, G. Fallara et al.· European Urology Oncology· 0 citations
